Home Health & Wellness Deep Pharma Intelligence Unveils Definitive Artificial Intelligence in Oncology IT Platform and Report

Deep Pharma Intelligence Unveils Definitive Artificial Intelligence in Oncology IT Platform and Report

Published: Last updated:
Reading Time: 2 minutes

Deep Pharma Intelligence, a leading BioTech market research agency focused on sophisticated analytics, benchmarking and forecasting of emerging and frontier domains in the Pharmaceutical, BioTech and Healthcare industries, announced the release of AI in Oncology Analytics Platform.

This platform is part of a series of AI in Pharma launches, alongside recently launched AI in Drug Discovery.

The AI in Oncology platform provides an in-depth overview of the industry landscape with interactive profiles, mindmaps, and databases of 140 companies, 475 investors and 20 hubs, all involved in the AI in Cancer Vaccines space and organised into seven key categories, including cancer research, cancer diagnostics, genome data analysis, drug development, cancer treatment, cancer screening, and immunotherapy development. 

AI companies are driving transformative advancements in oncology research and treatment, with total funding exceeding $5.8B as of August 2023. When examining FDA-approved artificial intelligence devices, the oncology-related speciality field shows that cancer radiology holds the largest share at 54.9%.

Pathology follows at 19.7%, while radiation oncology and gastroenterology account for 8.5% each. Clinical oncology represents 7.0% of the applications, with gynaecology contributing 1.4%.

 

AI in Oncology Analytics Platform at a glance

  • Mindmaps and databases of 140 companies, 475 investors and 20 hubs, all involved in the AI in Oncology Treatment space.
  • Information on the Top 100 AI in Oncology Leaders, with profiles on the leading researchers, scientists, entrepreneurs and technologists committed to harnessing the potential of AI to tackle the complex challenges of cancer treatment. 
  • The AI in Oncology Analytical Report provides an extensive perspective on the current status of AI in Oncology, spotlighting key stakeholders, trends, and technologies. The report includes a comprehensive analysis of the exponential surge in investments in AI-driven powered companies based on funding levels, with a focus on those with total funding exceeding $15M. 

The platform is further complemented by Pharma Big Data Analytics System and Dashboard for professional users seeking deeper, more specific and customised insights. The system provides sophisticated analytical and market intelligence capabilities, automated SWOT analysis, and AI-driven smart-matching tools.

As the role of AI continues to experience unprecedented growth, diversification, and disruption in the BioTech and HealthTech industries, extracting relevant insights for optimal strategic decision-making has become increasingly complex.

Leveraging advanced AI techniques and real-time analytics capabilities, Deep Pharma Intelligence’s comprehensive suite of in-depth analytical systems provides an understanding of the rapidly evolving AI in the BioTech and HealthTech landscape, delivering unique insights to industry stakeholders and decision-makers.

Upcoming platform iterations will spotlight AI applications in diabetes, FemTech, and cancer vaccines, shedding light on revolutionary therapies, key industry players, and prevailing trends.

© Copyright 2014–2034 Psychreg Ltd